INM InMed Pharmaceuticals Inc.: institutional ownership and insider trading
21 funds reported holding $5.18M of InMed Pharmaceuticals Inc. in their latest 13F filings; in Q2 2026 funds net bought $3.69M, with 13 new positions and 2 funds selling out; over the last 12 months insiders bought $1.36M and sold $0 on the open market.
Famous investors holding INM
- Ken Griffin (Citadel Advisors): $40.4K, 0.0% of the portfolio
Largest institutional holders of INM
- ADAR1 Capital Management, LLC — $1.24M
- Vivo Capital, LLC — $1.24M
- Banque Cantonale Vaudoise — $1.00M
- Squadron Capital Management LLC — $504K
- Ikarian Capital, LLC — $380K
- Ursa Fund Management, LLC — $195K
- SUVRETTA CAPITAL MANAGEMENT, LLC — $155K
- BOOTHBAY FUND MANAGEMENT, LLC — $115K
- SABBY MANAGEMENT, LLC — $69.7K
- JANE STREET GROUP, LLC — $66.8K
Recent INM insider trades
- Oct 19, 2026: Schneeberger Daniel bought 1,087 shares ($1.44K)
- Oct 15, 2026: Schneeberger Daniel bought 9,569 shares ($12.7K)
- Oct 8, 2026: Schneeberger Daniel bought 10,903 shares ($14.5K)
- Oct 5, 2026: Schneeberger Daniel bought 42,920 shares ($57.1K)
5%+ owners
- Vivo Opportunity Fund Holdings, L.P.: 21.7% (Schedule 13D, filed Jun 10, 2026)
- ADAR1 Capital Management, LLC: 17.2% (Schedule 13G/A, filed Oct 7, 2026)
- Squadron Master Fund LP: 9.8% (Schedule 13G, filed May 27, 2026)